Treatment for Diabetic Cardiomyopathy
Heart disease is the lead cause of mortality among diabetic patients in the U.S. UC San Diego researchers have developed a method to treat diabetic cardiomyopathy by gene therapy using an enzyme specific for the removal of a single sugar molecule from proteins such as transcription factors. The researchers demonstrated that elevated extra-cellular glucose levels result in impaired calcium cycling in myocytes, leading to impaired cardiac contractility and poor myocardial performance, by a mechanism involving O-linked glycosylation of nuclear proteins. They found that these effects can be reversed by gene therapy with an enzyme, O-GlcNAcase, which can remove specific O-linked hexosamines from proteins. Delivery of viral vectors encoding O-GlcNAcase to myocytes from diabetic rats markedly improved calcium flux and contractile function.
Patent Number: US7919475B2
Application Number: US2006574232A
Inventor: Dillmann, Wolfgang | Clark, Raymond
Priority Date: 25 Aug 2004
Priority Number: US7919475B2
Application Date: 30 Jan 2008
Publication Date: 5 Apr 2011
IPC Current: A61K004800 | A01N006300 | C07H002102 | C07H002104
US Class: 514044R | 42409321 | 435325 | 5360231 | 5360232
Assignee Applicant: The Regents of the University of California
Title: Compositions and methods for improving heart function
Usefulness: Compositions and methods for improving heart function
Summary: The pharmaceutical composition is useful for treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy.
Novelty: New pharmaceutical composition comprising an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid or protein or a compound that increases O-GlcNAc (OGT) transcription or activity, useful in treating heart disease
Biomedical
Medical Composition
7919475
Additional Technologies by these Inventors Tech ID/UC Case 19673/2004-071-0 Related Cases 2004-071-0
USA
